Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure ...

Since its introduction nine months ago, the FDA’s national priority voucher pilot program has attracted intrigue and fierce ...

As pharmaceutical companies face increasing pressure to produce more content across more channels, the Medical, Legal, and ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...

The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the ...

Not long after lending its support to a documentary aimed at shining a light on the often-overlooked stories of women with ...

It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

Since investment bank HSBC downgraded the stock of Eli Lilly from “hold” to “reduce” on Tuesday morning, the share price of ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives ...